L8668

Levetiracetam

≥98% (HPLC), powder, acetylcholine receptor inhibitor

• Synonym(e): (αS)-α-Ethyl-2-oxo-1-pyrrolidinacetamid, 2(S)-(2-Oxopyrrolidin-1-yl)-butyramid
• Empirische Formel (Hill-System): C₈H₁₄N₂O₂
• CAS-Nummer: 102767-28-2
• Molekulargewicht: 170.21
• UNSPSC Code: 12352200
• PubChem Substance ID: 329817665
• NACRES: NA.77
• MDL number: MFCD03265610
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Produktname: Levetiracetam, ≥98% (HPLC)
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white
• solubility: H₂O: >5 mg/mL
• originator: UCB Inc.
• SMILES string: CC[C@H](N1CCCC1=O)C(N)=O
• InChI: 1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
• InChI key: HPHUVLMMVZITSG-LURJTMIESA-N
• Gene Information: human ... CACNA1B(774), SV2A(9900)

Beschreibung

General description

Levetiracetam is a member of the pyrrolidone family, which is a second-generation anti-epileptic drug (AED). It acts as a neuroprotective and hyperalgesic drug. Levetiracetam is implicated in cholinergic neurotransmission.

Application

Levetiracetam has been used as an anti-epileptic drug to study its effects on glucose-mediated death.

Biochem/physiol Actions

Levetiracetam ist ein Pyrrolidin mit antiepileptischer Aktivität.

Levetiracetam ist ein Pyrrolidin mit antiepileptischer Wirkung. Stereoselektive Bindung von Levetiracetam ist auf synaptische Plasmamembranen im zentralen Nervensystem beschränkt, in peripherem Gewebe kommt es zu keiner Bindung. Levetiracetam hemmt das sogenannte "burst firing", ohne die normale neuronale Erregbarkeit zu beeinflussen.

Features and Benefits

This compound was developed by UCB Inc.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: dust mask type N95 (US), Eyeshields, Gloves